Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Harvard Bioscience to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023

HBIO

HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023.

Mr. Green will present on Tuesday, March 21 at 9:45 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.

Harvard Bioscience will also host virtual one-on-one meetings with investors on Tuesday, March 21, 2023.

To register for the presentation or to schedule a one-on-one meeting, please visit www.key.com/lsmt.

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at www.harvardbioscience.com.

Investor Contact:

Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
investors@harvardbioscience.com


Primary Logo

Tags: